Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (December 2014)
44 slides from Fluoropharma Medical's investor presentation, Dec 12, 2014
Slide 1: Enabling Personalized Medicine Through Precision Diagnostics
Enabling Personalized Medicine Through Precision Diagnostics. (OTCQB:FPMI)
Slide 2: Forward-Looking Statements
Fluoro Forward-Looking Statements Pharma This presentation contains “forward-looking statements’ within the meaning of the Securities Act of 1933, as amended, the ige Act of 1934, as |, and the Private Litigation Reform Act of 1995, which are intended to be covered by the safe harbor created thereby
Slide 3: Every
Every Patients will die of heart disease A cardiac perfusion scan is performed Portfolio of s, compounds in heart disease ai BFPET CardioPET VasoPET | www. FluoroPharma.com
Slide 4: FluoroPharma At-a-Glance
FluoroPharma At-a-Glance Fluoro.- Pharma THE COMPANY CORE EXPERTISE THREE ACTIVE CARDIAC IMAGING PROGRAMS FOR PET IMAGING CLINICAL BENEFITS PATIENT MANAGEMENT + Founded in 2003 in Boston with technology licensed from Massachusetts General Hospital + Next generation molecular imaging drugs for diagno
Slide 5: Molecular Imaging Allows 3D Visualization of the Heart
Fluoro Molecular Imaging Allows 3D Visualization of the Heart arma www.FluoroPharma.com.
Slide 6: Molecular Imaging Allows 3D Imaging and Motion
Fluoro Molecular Imaging Allows 3D Imaging and Motion www.FluoroPharma.com.
Slide 7: FluoroPharma Medical Inc. Development Portfolio
FluoroPharma Medical Inc. Development Portfolio For diagnosis of acute and chronic For targeted detection of CAD inflammetory plaques 12 million potential patients | |* 17 million potential patients | | 56 million potential patients For use in combination with | |* Detects regions of fatty acid || =
Slide 8: Cardiovascular Disease is a Major Global Health Burden
Cardiovascular Disease is a Major Global Health Burden: Fluoro Pharma ath ER& KEY FACTS - US AND WW WHO: ‘Neglected Global Epidemic” + 16.7M deaths WW: 1/3 of all deaths, 78% from low / middle income countries. + 113 of deaths in China, % in Europe + 2.4M deaths US: top cause (38.5%) KEY UNMET NEEDS
Slide 9: Coronary Artery Disease Treatment Flow Model
Fluoro. Coronary Artery Disease Treatment Flow Model Pharma Origination Evaluation ndiagrosed CAD Patent ‘eis ener ee (oe ei + Non Hospital * Hospital Outpatient Ness Ta Rest + Hospital inpatient Dele encaraaeEvausten) [Medical Tern, ‘Suatoges, magne i3 T wwww.FluoroPharma.com sat. reecio soon ont 2
Slide 10: Patients With Known or Suspected CAD: Decision Tree
Patients With jown or uspected CAD: Decision Ti Pharr Stress Imaging + Viability Imaging + Stress induced ischemia + Hibernation + LV function More aggressive www. Flare BMA: ABart. 2004:90(Suppl V):v26-v33.
Slide 11: BFPET Should Provide Superior Performance in Both PPV and NPV
.Fluoro — BFPET Should Provide Superior Performance in Both PPV and NPV: ~~ > Pharma ‘As shown below, BFPET images have higher resolution than mark dard SPECT ona basis. Sestamibi Standard of Care | | BFPET j ..while BFPET clearly showed that this patient's myocardium was actually healthy. On SPECT
Slide 12: BFPET Clinical Use
Fluoro BFPET Clinical Use Pharma MYOCARDIAL PERFUSION IMAGING * Evaluate patients with known or suspected CAD + Evaluate CAD in patients that can tolerate exercise as well as pharmacologic stress CURRENT DIAGNOSTIC TEST + Perfusion imaging with SPECT tracers (e.g. MIBI, tetrofosmin, T-201) or Rb-82
Slide 13: BFPET Images Heart Disease at Higher Resolution
Fluoro, BFPET Images Heart Disease at Higher Resolution Pharma BFPET's extremely high resolution allows the cardiologist to differentiate among ischemic, infarcted, and healthy myocardium. As shown below, BFPET images have higher resolution than market-standard sestamibi on a qualitative basis. On S
Slide 14: 18-F TPP (BFPET)
18-F TPP (BFPET) Source: Investigator Initiated Trial; PLA 304, Beijing. China. Courtesy Dr. Tien
Slide 15: The BFPET Opportunity: United States
Fluoro The BFPET Opportunity: United States Pharma Est. PET Market Market Procedures EY Myocardial perfusion imaging 22 Million 4.8 million i 50 Projected BFPET Scans Projected BFPET Revenue $ Go wiLLoNs to EEE 50 40 30 20 10 00 7 | www.FluoroPharma.com ‘Source: Black Swan Analysis, Fluoropharma Mar
Slide 16: Cost Effectiveness Will Drive Referrals and Reimbursement to Cardiac PET
Cost Effectiveness Will Drive Referrals and Fluoro Reimbursement to Cardiac PET Pharma Drivers and Benefits: Cary V. Heer MO, PO“ attention © Expansion of clinical indications/clinical needs Lower radiation dose Improved diagnostic accuracy Improved patient outcomes, nln ene tment (PED mang PET te t
Slide 17: Physicians Express Strong Willingness to Utilize BFPET Once Approved
Physicians across the US and EU have expressed a Fluoro very strong willingness to utilize BFPET once it is approved Pharma In blinded research, the product profile for BFPET gained very positive responses from specialists where indicated a willing to increase estimates use after more comfort. Key T
Slide 18: Pharma
Pharma Impaked FA oxidation Spptoue www.FluoroPharma.com
Slide 19: Heart Failure is Reaching Epidemic Proportions
Fluoro Heart Failure is Reaching Epidemic Proportions: Pharma $ billion HE Cost US: $20.00 * ~70% of HF is driven by ischemic Sram 127% heart disease panes * The average life expectancy after HF _ si cont diagnosis is 8 years, 50% die within 5 ssand + HF prevalence is expected to increase $2000 46%
Slide 20: FCPHA (CardioPET) Results
FCPHA (CardioPET) Results Pharma Noumea CAD Subject Subiect 2 Fatty acid analog that detects regions of metabolic insufficiency PHASE | TRIAL COMPLETED (45 NHV and 6 CAD patients) => CardioPET promising safety with no AEs detected Clinical findings consistent with MPI SPECT Quality of CardioPET imag
Slide 21: Phase II CardioPET Data is Starting to Be Presented
Phase II CardioPET Data is Starting to Be Presented Fluoro BEART éioPET PHASE 1 STUDY SAFETY, IMAGE QUALITY AND OPTIMAL esis ten) eevee TIMING FOR MYOCARDIAL IMAGING USING Ec ay apes me cn aa oe THE F-18 FATTY ACID ANALOG CaRDioPET IN oe sees ee KNOWN OR SUSPECTED CAD PATIENTS Sed ie ee rematesendae
Slide 22: SNMMI Poster on CardioPET Quantitation
SNMMI Poster on CardioPET Quantitation ( Fluoro Pharma fF UZyyen Quantification of myocardial perfusion in humans by PET/CT AN and the fatty acid analogue **F-FCPHA: a feasibility study ron bg FAG. Cowanton aes Pe CT Be con ata od Spe So wre i ed ‘Showin en ce ws ers 21 0 enya nie 8508700, 8 theses
Slide 23: SNMMI Poster on CardioPET Quantitation (2/2)
SNMMI Poster on CardioPET Quantitation (2/2) Fluoro ; Pharma ctuifiiit ‘One compartment two parameter model Individual global myocardial ie activi sed forth study Sate "EFCPHA images from 28 minutes were ‘compared with corresponding "Te MIL SPECT Images. Stress "PFCPHA images visual eveled Deruson d
Slide 24: Images That Teach
2 Vessels on SPEC Vessels CardioPET and Angiograp! IMAGES THAT TEACH ‘A new F-18 labeled PET tracer for fatty acid 8 Pharma www. FluoroPharma.com a
Slide 25: CardioPET Clinical Use
Fluoro CardioPET Clinical Use Pharma DIAGNOSIS OF CAD AT REST + Evaluate CAD in patients that cannot exercise CARDIAC VIABILITY ASSESSMENT *+ Identify patients that may benefit from PCI or revascularization and guide intervention CURRENT TREATMENT * Invasive coronary angiography CLINICAL NEED + 1.3
Slide 26: CardioPET May Provide a Critical Direction in a Diagnosis of Exclusion
CardioPET may provide a critical direction in a diagnosis of exclusion ~ Pharma Physicians indicate they would employ CardioPET when a patient presents with a equivocal ACS—typically, when the patient has a “strong story” of chest pain and shortness of breath but shows up as negative on initial test
Slide 27: The CardioPET Opportunity: United States
The CardioPET Opportunity: United States Commercial Assumptions | 1$-20ni Jon Market Procedures St PET Market Procedures CAD diagnosis at rest. 38 millon 1.4 million Cardiac viability easly 1.6 million 0.5 milion Myocardial perfusion , imaging cas ahs Courtesy of abla Demeue, UCL, Belgum Projected C
Slide 28: 18-F FCPHA (CardioPET)
18-F FCPHA (CardioPET) PET/CT Fusion on Modern Scanners Gives Anatomy and Function
Slide 29: Why PET, and Why Now
Why PET, and Why Now: Fluoro Distribution, infrastructure and increasing installed base Pharma + PET has a significantly higher rate of specificity and sensitivity than SPECT icc UIs) + Leads to decreased attenuation artifacts and fewer inconclusive studies VN JeulSIGWI) « Provides a more accurate d
Slide 30: Substantial Installed Base in the US
Substantial Installed Base in the US Fluoro Pharma ~2800 Scanners Operating at ~40% Capacity Cardiac stress tests are already performed more than 60% of the time at centers with PET machines. The PET machines are currently imaging oncology patients for 95% of their workload Distribution of PET Machi
Slide 31: Production of Finished Material: Established Cyclotron Distribution Network
Production of Finished Materi The US Has an Established Cyclotron Distribution Networ Pharma Approximately 100 FDG production sites (Cardinal Health, IBA, PETNET) will allow FluoroPharma to provide a high level of customer service, enabling product delivery within two to three hours to 85% of PET in
Slide 32: Experienced Management Team and Advisors
Fluoro Experienced Management Team and Advisors Pharma This Spoor President. CEO + Healthcare executive with >45 years medical industry experience + Former securities analyst at P Morgan and Credit Suisse covering medical devices and biotechnology * Lad the nuclear cardiology portfolio and PET new p
Slide 33: Investment Highlights
Fluoro Investment Highlights Pharma Radiopharmaceutical company with two next generation cardiovascular perfusion imaging agents in Phase 2 + Short Study Timelines/regulatory pathway + Available data already demonstrates better imaging characteristics than traditional SPECT + Established reimburseme
Slide 34: Enabling Personalized Medicine Through Precision Diagnostics
Enabling Personalized Medicine Through Precision Diagnostics. (OTCQB:FPMI)
Slide 35: MI Growth to be Driven Largely by Emerging Markets
MI Growth to be Driven Largely by Emerging Markets Fluoro - Pharma Global Medical Imaging Equipment Market’: Revenue Outlook by Geographic Region, World, 2012-2017 Total Revenue (2012) = $24,062.3 Million, Total CAGR (2012-2017) = 4.4% 120 ) Lower Revenue, Higher Growth Higher Revenue, Higher Growth
Slide 36: Diabetes is Driving Cardiovascular Disease Worldwide
Diabetes is Driving Cardiovascular Disease Worldwide: Fluoro Phar + Diabetes doubles your risk of CVD and stroke + Acute M's in patients with diabetes has doubled since 1999 + Prevalence in 12-19 year-olds has nearly tripled since 2000 + Jin 5 healthcare dollars touches diabetes www.FluoroPharma.com
Slide 37: Cardiovascular Molecular Imaging Landscape
Cardiovascular Molecular Imaging Landscape Fluoro — Pharma Company SPECT Market Cap ‘Bracco CardioGen (Rb-82) Private ($1.28 sales) Cardinal Health ‘Te-99m Sestamibi, - $248 FluoroPharma Mecival 2 si04M GE Healthcare ‘Te-99m Myoview es $6B Jubilant (Draximage) ‘Te-99m Sestamibi RUBY-FILL (Rb-82) $31
Slide 38: Diagnostic Imaging Segments
Fluoro Diagnostic Imaging Segments Pharma Global Medical Imaging Equipment Market: Revenue Breakdown by Geographic Region and Imaging Modality, World, 2012 100 General Xray 80 J Mammogrephic Xray Interventional X- ray g H ct é 2 40 Utrasound ° | A. magne ° ; 5 10 5 20 24a North America Europe Russia
Slide 39: Hardware / Technology Comparison
Hardware / Technology Comparison: Higher Expectations for PET Replacement Time, Years PET technology is refreshed at a faster rate than SPECT GEEEEEEE Replacement rate is trending to surpass SPECT. Mie) Pharma ‘Aging SPECT cameras are performing fewer studies PET SPECT 20% 2% 15% 8 @ ye 6 158 ” 20%,
Slide 40: Coronary Angiography or Intervention Clinical Path
Fluoro onary Angiography or Intervention Pharma Clinical Path) Patients sent for myocardial perfusion imaging Inducible ischemia Referral to catheterization Referral to revascularization AST SO et Se sone moran menenton
Slide 41: Fluoro
Fluoro Pharma 131. eehomi ear eaeas monatty, 2011 and change 190-2011 nearest yur ‘Change 1990-2011 1 over te por ne 5 i li 10-75-50 25 0 2 7S Rinna FO nor BER rete O ‘nfrmatn Star saa hp ie da oy 10 17877080902315602. ‘Source: OECD Heal Sade 013 (exacted om WHO), Mp. Slr. 7B7hadh an, www.FluoroPhar
Slide 42: Molecular Imaging of CVD
Fluoro Pharma Molecular Imaging of CVD ‘vB Integrin Ischemia —> Infarction > Remodeling Atherosclerosis —» Plaque Rupture Reduced Perfusion [recional Myocardial Dyotd Inflammation —> Thrombosis —+ Apoptosis—> Necrosis — Fibrosis FDG Wotlla ‘Annexin V)_{ Pyrophosphate MMPs Myosin Thrombin (lla) Caspa
Slide 43: Contemporary View of Heart Failure
Fluor Contemporary View of Heart Failure Pharm. Myocardial Dysfunction —— M Increased Load/Reduced Systemic Perfusion Mh Activation of RAS, SNS, Cytokines i—| y v — a>. —_ oe aaa Energy Depletio Toxicity J os Adepted rom Braunwalds ees cet DEATH |__| www.FluoroPharma.com. >| Growth ee Remodeling
Slide 44: Enabling Personalized Medicine Through Precision Diagnostics
Enabling Personalized Medicine Through Precision Diagnostics
FluoroPharma Medical — Investor Presentation (December 2014) on 6ix